Market Place
Sourcing Support
Roche Partners With COUR in Autoimmune Deal Worth $900M
04 Dec 2024 //
BIOSPACE
COUR Signs Licensing Deal with Genentech for Autoimmune Therapy
03 Dec 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Doses First Patient in Myasthenia Trial
30 Oct 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Presents Phase 2a Data For CNP-104
21 Oct 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Reports Positive Ph 2a Results For CNP-104
30 Sep 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Announces Leadership Transition
01 Aug 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
26 Jun 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer
21 May 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Secures $105 Million in Series A Financing
30 Jan 2024 //
GLOBENEWSWIRE
COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer
19 Jul 2023 //
PR NEWSWIRE
COUR Pharma Announces Robert F. Carey Joins Board of Directors
08 Feb 2023 //
GLOBENEWSWIRE
COUR, Boehringer, Genentech, GSK, & Idorsia to Keynote at Veeva Summit
15 Nov 2022 //
PRNEWSWIRE
COUR Announces FDA Clearance of Investigational NDA for Myasthenia Gravis
25 Oct 2022 //
PRNEWSWIRE
COUR PHARMACEUTICALS APPOINTS BRIAN C. BOCK AS CHIEF FINANCIAL OFFICER
28 Feb 2022 //
PRNEWSWIRE
COUR Pharmaceuticals Receives FDA FTD for CNP-104 in Primary Biliary Cholangitis
10 Jan 2022 //
PRNEWSWIRE
COUR Begins Dosing in Proof-of-Concept Trial of CNP-201 for Peanut Allergy
19 Oct 2021 //
PRNEWSWIRE
USFDA Accepts COUR Pharma Investigational IND for a Proof-of-Concept Study
04 Oct 2021 //
PRNEWSWIRE
FDA Accepts NDA for Peanut Allergy Candidate Developed by COUR Pharmaceuticals
16 Sep 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.